Basal cell carcinoma secondary prevention

Basal cell carcinoma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Basal Cell Carcinoma from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
Staging
History and Symptoms
Physical Examination
Laboratory Findings
CT scan
MRI
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Basal cell carcinoma secondary prevention On the Web
Most recent articles
cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Basal cell carcinoma secondary prevention All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Basal cell carcinoma secondary prevention
CDC on Basal cell carcinoma secondary prevention
Basal cell carcinoma secondary prevention in the news
Blogs on Basal cell carcinoma secondary prevention
Directions to Hospitals Treating Basal cell carcinoma
Risk calculators and risk factors for Basal cell carcinoma secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Saarah T. Alkhairy, M.D.

Overview

The use of a chemotherapeutic agent such as 5-Fluorouracil or Imiquimod, can prevent the further development of skin cancer.

Basal Cell Carcinoma Secondary Prevention

• Skin biopsy
• Chemotherapeutic agents such as 5-Fluorouracil or Imiquimod

• It is usually recommended to individuals with extensive sun damage, history of multiple skin cancers, or precancerous growths
• It is often repeated every 2 to 3 years